- 2 dependent manner after major lumbar fusion surgery: a randomized, double-blind,
- 3 placebo-controlled clinical trial
- 5 Elina C.V. Brinck<sup>1,2,#a</sup>, Taru Virtanen<sup>3,¶, #b</sup>, Sanna Mäkelä<sup>4</sup>, Venla Soini<sup>5</sup>, Ville-Veikko
- 6 Hynninen<sup>4</sup>, Jukka Mulo<sup>4</sup>, Urmas Savolainen<sup>4</sup>, Juho Rantakokko<sup>5</sup>, Kreu Maisniemi<sup>1</sup>, Antti
- 7 Liukas<sup>3</sup>, Klaus T. Olkkola<sup>2</sup>, Vesa Kontinen<sup>6</sup>, Pekka Tarkkila<sup>1</sup>, Marko Peltoniemi<sup>3</sup>, Teijo I.
- 8 Saari<sup>3,4, #b</sup>

4

- <sup>1</sup>Department of Anaesthesiology, Töölö Hospital, Division of Anaesthesiology, Intensive Care
- and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki,
- 11 Finland
- <sup>2</sup>Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of
- 13 Helsinki and HUS Helsinki University Hospital, Helsinki, Finland
- <sup>3</sup>Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland
- <sup>4</sup>Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku
- 16 University Hospital
- <sup>5</sup>Division of the musculoskeletal system at Turku University Hospital, Turku University
- Hospital, Department of Orthopaedics, University of Turku, Turku, Finland.
- <sup>6</sup>Department of Anaesthesiology, Jorvi Hospital, Division of Anaesthesiology, Intensive Care
- and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki,
- 21 Finland

- <sup>#a</sup> Current address: Department of Anesthesiology, Töölö Hospital, HUS Helsinki University
- 23 Hospital, Helsinki, Finland
- <sup>#b</sup> Current address: Department of Anaesthesiology and Intensive Care, University of Turku,
- 25 Turku, Finland
- \* Corresponding author
- 28 Email: teisaa@utu.fi (TIS)

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

BACKGROUND: Spinal fusion surgery causes severe pain. Strong opioids, commonly used as postoperative analgesics, may have unwanted side effects. S-ketamine may be an effective analgesic adjuvant in opioid patient-controlled analgesia (PCA). However, the optimal adjunct Sketamine dose to reduce postoperative opioid consumption is still unknown. METHODS: We randomized 107 patients at two tertiary hospitals in a double-blinded, placebocontrolled clinical trial of adults undergoing major lumbar spinal fusion surgery. Patients were randomly allocated to four groups in order to compare the effects of three different doses of adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml-1) or placebo on postoperative analgesia in oxycodone PCA. Study drugs were administered for 24 hours postoperative after which oxycodone-PCA was continued for further 48 hours. Our primary outcome was cumulative oxycodone consumption at 24 hours after surgery. RESULTS: Of the 100 patients analyzed, patients receiving 0.75 mg ml<sup>-1</sup> S-ketamine in oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg) compared with patients receiving 0.5 mg ml<sup>-1</sup> (74.7 mg) or 0.25 mg ml<sup>-1</sup> (74.1 mg) S-ketamine in oxycodone or oxycodone alone (81.9 mg) (mean difference: -20.6 mg; 95% confidence interval [CI]: -41 to -0.20; P = 0.048). A significant beneficial effect in mean change of pain intensity at rest was seen in the group receiving 0.75 mg ml<sup>-1</sup> S-ketamine in oxycodone PCA compared with patients receiving lower ketamine doses or oxycodone alone (standardized effect size: 0.17, 95% CI:

0.013-0.32, P=0.033). The occurrence of adverse events was similar among the groups.

- 49 CONCLUSIONS: Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1: 0.75
- 50 decreased cumulative oxycodone consumption at 24 h after major lumbar spinal fusion surgery
- 51 without additional adverse effects.

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Severe postoperative pain is common after major spinal fusion surgery. Inadequate pain management is associated with increased postoperative complications, delayed ambulation, and chronic postoperative pain.<sup>2</sup> This may lead to unplanned readmission after surgery, decreased patient satisfaction, and increased health-care costs. Opioids have been the cornerstone of postoperative analgesia after major surgery, but the increasing awareness of the problems associated with their use, such as opioid-associated adverse effects, opioid-induced hyperalgesia, and the risk of addiction, combined with the current opioid crisis has encouraged the search for alternative analgesic strategies. Multimodal analgesia targets different pain signaling pathways by combining two or more analgesic modalities, aiming at additive or even synergistic analgesic effect.<sup>3</sup> Multimodal analgesia has proven feasible after major spinal fusion surgery in an effort to optimize pain relief while minimizing opioid-related adverse effects.<sup>4,5</sup> Patient-controlled analgesia (PCA) use is associated with lower pain intensity and greater patient satisfaction compared with conventional (oral, subcutaneous, or intramuscular) administration routes. PCA may enhance patient autonomy because the analgesic drug is readily available. Morphine is the most frequently used opioid in PCA, while oxycodone use is associated with higher patient satisfaction scores.<sup>6,7</sup> Low-dose (<1 mg kg<sup>-1</sup>) ketamine inhibits N-methyl-D-aspartate receptors in nociceptive neurons and activates descending inhibitory pain pathways, resulting in attenuated wind up and central sensitization. 8-11 The effect of perioperative intravenous ketamine as an adjunct analgesic has been documented in several clinical trials and meta-analyses. <sup>12</sup> A recent review article concluded

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

5

that combining ketamine with an opioid in IV-PCA during the postoperative period has a beneficial effect on analgesia and opioid consumption.<sup>13</sup> In orthopedic surgery, earlier trials found negative or unclear results with opioid-ketamine PCA. 14-16 However, studies' vast heterogeneity and small sample sizes have failed to establish a possible a possible doseresponsiveness. Thus, the optimal ketamine to opioid ratio in intravenous PCA is yet to be elucidated. We hypothesized that adjunct S-ketamine with oxycodone in an intravenous PCA is superior to oxycodone, with reduced opioid-associated adverse events in the immediate postoperative period after major spinal surgery. This randomized, double-blind, placebo-controlled study compared three different doses of S-ketamine with placebo added as an adjuvant to oxycodone IV-PCA administered for 24 hours after lumbar spinal fusion in adult patients. After the study phase, IV oxycodone-PCA without ketamine was continued for further 48 hours. The primary outcome was cumulative oxycodone consumption at 24 h after surgery. The secondary endpoints included postoperative pain intensity, oxycodone consumption, and occurrence of adverse events up to 72 h after surgery.

92

93

94

95

96

97

98

99

100

101

102

103

104

105


106

107

6

posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation under

general anesthesia were recruited between 6 February 2017 and 31 October 2019 (Fig 1).



**Figure 1.** DoseRespKeta trial structure and CONSORT 2009 flow diagram. CONSORT indicates Consolidated Standards of Reporting Trials.

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

8

double blinding. Patients, researchers, and clinical staff were blinded to group allocation.

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

After providing written informed consent, patients learned to use the PCA system (CADD®-Solis VIP and CADD-Legacy® PCA Pump Model 6300, Smiths Medical, Minneapolis, MN, USA) and numerical rating scale (NRS; 0 denotes no pain, and 10 indicates the worst imaginable pain). Preoperatively, all patients received 1000 mg of paracetamol orally. Routine anesthetic monitoring included pulse oximetry, electrocardiography, invasive blood pressure via radial artery cannulation, and body temperature measurement. General anesthesia was induced and maintained with propofol (Propofol-Lipuro 20 mg ml<sup>-1</sup>; B. Braun Melsungen AG, Melsungen, Germany) and remifentanil (Remifentanil B. Braun 1 mg ml<sup>-1</sup>; B. Braun Melsungen AG, Melsungen, Germany) target-controlled infusions. Schnider- and Minto-effect-site models were used for propofol and remifentanil, respectively. 17,18 No opioids other than remifentanil were used before or during anesthesia. Rocuronium bromide (Esmeron 10 mg ml<sup>-1</sup>; Merck Sharp & Dohme B.V., BN Haarlem, The Netherlands) 0.4–0.6 mg kg<sup>-1</sup> facilitated endotracheal intubation. The depth of anesthesia (bispectral index BIS or entropy index) was targeted from 45 to 55 with entropy (GE B850 Monitor Entropy Module, GE, Helsinki, Finland) or BIS monitor (The Philips BIS module, Philips Medical Systems, Eindhoven, The Netherlands). Mean arterial pressure (MAP) was maintained at 65–75 mmHg. Intravenous bolus doses of ephedrine and/or noradrenaline infusion were administered if necessary. Local anesthetic was injected to the skin incision area before incision (lidocaine 5 mg kg<sup>-1</sup> c. adrenaline 5 µg kg<sup>-1</sup>; Orion Pharma, Espoo, Finland) and after wound closure (levobupivacaine 2.5 mg kg<sup>-1</sup>; Chirocaine 2.5 mg ml<sup>-1</sup>, AbbVie S.r.l., Campoverde di Aprilia, Italy) as per hospital routines. At the end of surgery, the PCA pump was attached to the intravenous line and activated. The first dose of PCA solution was given just after the cessation of propofol and remifentanil infusions,

before patients woke up from anesthesia. As soon as the patient awoke, they were encouraged to use PCA to treat postoperative pain if necessary. The starting dose of oxycodone (Oxycodone Orion 10 mg ml<sup>-1</sup>; Orion Pharma, Espoo, Finland) in the PCA solution was 2 mg with a lockout interval of 5 min. When NRS was 4 or lower, the PCA oxycodone dose was decreased to 1 mg (G1–G4). The study PCA dosing continued for 24 h from the end of surgery. Thereafter, the PCA cassette was changed to only an oxycodone-containing solution (G1). The total duration of PCA treatment was three days. Postoperative nausea and vomiting (PONV) were treated with intravenous ondansetron and dehydrobenzperidol if necessary. Potential excessive unpleasant psychotomimetic effects from S-ketamine (Ketanest-S 5 mg ml<sup>-1</sup>; Pfizer Manufacturing Belgium NV, Puurs, Belgium) were treated with 1 mg intravenous bolus of lorazepam. Measurements and data handling Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, NRS (0–10) for pain intensity at rest and upon movement, level of sedation with the Richmond Agitation-Sedation scale (RASS), nausea, vomiting, pruritus, unpleasant dreams or any other adverse effect or sensation thought to be caused by PCA, cumulative PCA pressings, or the doses given were registered immediately after arrival in the recovery room and at the following time points: five, 30, 60, 120, and 240 minutes and eight, 24, 48, and 72 hours later. Patients evaluated their pain relief satisfaction (yes/no) at the end of postoperative days 1–3. All clinical patient data were collected on individual case report forms. All data were

subsequently transferred to electronic format for exploratory data analysis.

Primary and secondary outcomes

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

The primary endpoint was cumulative oxycodone consumption at 24 h after surgery, the end of period when three different ratios of S-ketamine were added to oxycodone PCA solution. Secondary outcomes were NRS and RASS ratings, oxycodone consumption, PONV, pruritus, and unpleasant dreams or other adverse effects. Sample size calculation Based on a previous study, <sup>19</sup> we calculated that 25 patients per group were necessary to demonstrate a clinically significant 25% reduction in oxycodone consumption with a level of significance of P = 0.05 and power of 80%. Statistical analyses The authors approved the statistical analysis plan before the analyses began. Explorative data analysis was conducted before statistical inference by plotting and tabulating the data. Normality assumptions were tested before analysis, using probit plots and the Shapiro-Wilk W-test. Levene's test was used to evaluate homogeneity of variances. The primary outcome measure, cumulative opioid consumption during the first 24 h is presented as both median and interquartile range (IQR; Q1–Q3) and mean (SD). Cumulative opioid consumption at 24, 48, and 72 h was analyzed by using a linear mixed model for repeated measurements. The model included the following factors: PCA dosing groups G1-G4, age (as a continuous covariate), age, gender, prior use of opioids (yes/no), prior use of gabapentinoids (yes/no), cumulative amount of dose requests during PCA, and postoperative time (24, 48, and 72 h). In addition, the interaction with time and opioid consumption and prior use of weak opioids was examined. Non-significant terms were excluded from the final model. An

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

unstructured covariance structure was used. Square-root transformation was used to fulfill assumptions of the model. Studentized residuals were used to check assumptions. To study pain burden, we analyzed if the mean change in NRS over time differed between the groups during the first 24 hours postoperatively. A hierarchical linear mixed model was used including time as a within-factor (with five time points), PCA dosing group as a between-factor, and their interaction. The time factor was handled as categorical to estimate all possible shapes of mean changes over time. NRS values were standardized before analysis by centering and scaling to have a mean of zero and a SD of one. Effect sizes were computed as the eta squared based on the H-statistic.<sup>20</sup> We also studied in a separate model, whether age, sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids affected the results. Differences in NRS and sedation (measured with RASS) between the groups were evaluated at the end of postanesthesia care unit (PACU) treatment (t = 480 min) and at 24 h with a Kruskal–Wallis test. Differences in postoperative nausea and vomiting, pruritus, and unpleasant dreams (yes/no) among groups at 24, 48, and 72 h postoperatively were evaluated with ordinal logistic regression. The effect of age, sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids on the results were tested as covariate effects. To analyze the effect of adjuvant ketamine treatment on these parameters, we included changes in parameters to the model during the previous 24 h. Descriptive statistics are shown as means and SD when variables are normally distributed and otherwise as medians and IROs. Categorical variables are summarized as counts and percentages. The statistical significance level was set to P < 0.05. RStudio (version 1.0.153)<sup>21</sup> with R (version 3.6.0)<sup>22</sup> and ggplot2 (version 2.2.1) were used for statistical analyses and graphical presentations.

Results

A total of 231 patients were assessed for eligibility. 107 patients were recruited in the study (Fig 1B) between February 2017 and October 2019. Two patients withdrew their consent before randomization and were excluded. Two patients were further excluded due to logistical reasons before surgery. In one case, the operation plan was changed after randomization and this patient was also excluded from the study. Two more patients withdrew consent during the first 24 h after the start of intervention and were excluded from the final analysis. Thus, 25 patients in each of the four groups were included in the analysis. Patient median age was 60 (28–78) years and 77% were women. No significant differences in baselines characteristics were present among the groups (Table 1).

 Table 1. Perioperative Data and Characteristics of Patients Who Were Included in the Analysis.

	All	G1	G2	Standardized Differences Between G1 and G2	G3	Standardized Differences Between G1 and G3	G4	Standardized Differences Between G1 and G4
n	100	25	25		25		25	
Age, yr (median, range)	60 (28-78)2	56 (34-78)	62 (28-76)	0.214	60 (40-75)	0.433	62 (30-76)	0.329
Female/male, n (%)	45/55	11/14 (44%)¹	11/14 (44%)	<0.001	12/13 (48%)	<0.001	11/14 (44%)	0.08
Body weight (kg)	77.7 (15.6)	77.7 (15.6)	74.9 (15.9)	0.215	79.0 (14.1)	0.278	77.0 (11.2)	0.156
BMI (kg/m <sup>-2</sup> )	26.9 (4.3)	26.6 (4.6)	27.3 (4.3)	0.003	26.9 (3.5)	0.152	26.8 (4.9)	0.063
Smoking (yes/no), n (%)	9/91	1/24 (4%)	3/22 (12%)	0.169	3/22 (12%)	0.298	2/23 (7.7%)	0.298
Previous chronic pain (yes/no), n (%)	15/85	22/3 (88%)1	19/6 (76%)	0.115	22/3 (88%)	0.316	22/3 (88%)	<0.001
Median [IRQ] preoperative pain intensity (NRS)	6 [4, 8]	6 [5, 7]	5 [5, 7]	0.1	7 [5. 8]	0.42	7 [5. 8]	0.023
Preoperative opioid (yes/no), n (%)	5/94	2/23 (8.0%)1	2/23 (8.0%)	0.169	0/25 (0%)	<0.001	1/24 (3.8%)	0.417
Preoperative gabapentinod (yes/no), n (%)	18/82	3/22 (12%)1	3/22 (12%)	0.22	7/18 (28%)	<0.001	5/20 (19%)	0.408
Diabetes (yes/no), n (%)	8/92	1/24 (4.0%)1	3/22 (12%)	0.169	1/25 (4.0%)	0.298	3/22 (11%)	<0.001
ASA physical status, n (%)				0.408		0.182		0.331
1	24	7 (28.0)	6 (24.0)		6 (24.0)		5 (20.0)	
2	66	17 (68.0)	15 (60.0)		17 (68.0)		17 (68.0)	
3	10	1 (4.0)	4 (16.0)		2 (8.0)		3 (12.0)	

Duration of surgery (min)	306 (94)	325 (89)	292 (64)	0.424	303 (125)	0.202	305 (89)	0.226
Propofol during surgery (mg□kg <sup>-1</sup> )	37 (12)	39 (11)	36 (8)	0.259	35 (17)	0.26	36 (10)	0.248
Remifentanil during surgery _(µg□kg-¹□min-¹)	0.12 (0.05)	0.13 (0.06)	0.12 (0.04)	0.27	0.11 (0.04)	0.429	0.11 (0.04)	0.383

- Data are mean (standard deviation) or [range) unless otherwise stated. Standardized difference is the difference in the mean of a variable between 2 groups divided by an estimate of the standard deviation of that variable.<sup>21</sup>
- G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine

  0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled

  intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).; n, number of non-missing value; BMI, body-mass index; IQR,

  interquartile range; NRS, numerical rating scale; ASA, American Society of Anesthesiologists.
  - <sup>1</sup>Percentage of females or yes-answers


Opioid consumption

239

250

0.838).

240 Cumulative oxycodone consumption was highest in group G1 and lowest in G4 (Fig 2, Table 2). 241 The median total oxycodone consumption during the first 24 h after surgery was 81.9 mg (IQR: 242 63.2–101), 74.1 mg (IQR: 62.1–86.1), 74.7 mg (IQR: 62.2–87.1), and 61.3 mg (IQR: 48.7–73.8) in groups G1–G4, respectively. Postoperative cumulative oxycodone consumption was 243 244 significantly reduced in the group with the highest ketamine concentration (G4) compared with the control group (G1): the mean difference was -21 mg (95% CI: -41 to -0.2, P = 0.048), -26 245 mg (95% CI: -55 to -6.2, P = 0.044) and -41 mg (95% CI: -68 to -14, P = 0.003) at 24, 48, and 246 247 72 h after surgery, respectively (Fig 2). There was no significant difference in time to dose reduction from 2 mg to 1 mg PCA-bolus among groups (median [IQR]: 125 min [78–203], 127 248 min [82–174], 112 min [69–185] and 145 min [79–211] in groups G1–G4, respectively, P =249



**Figure 2.** Postoperative cumulative oxycodone consumption during the first 24 h in four patient-controlled analgesia (PCA) treatment groups (G1¬—G4). PCA, patient-controlled analgesia. Box plots show the median and 25–75th percentiles, and the whiskers indicate the minimum and maximum. Blue diamonds show the mean oxycodone consumption in each plot.

Table 2. Oxycodone consumption during the study after the beginning of PACU care


Time offer DAOLL start	All	G1	G2	G3	G4	
Time after PACU start	(n=100)	(n=25)	(n=25)	(n=25)	(n=25)	
60 min						
Mean (SD)	10.9 (4.2)	11.9 (3.4)	10.3 (3.9)	11.3 (4.2)	10.4 (5.1)	
Median [IRQ]	10.0 [8.00, 14.0]	12.0 [8.0, 16.0]	10.0 [7.40, 14.0]	10.0 [8.0, 14.0]	12.0 [6.00, 14.0]	
120 min						
Mean (SD)	19.2 (7.2)	21.2 (6.6)	18.2 (5.6)	20.0 (8.5)	17.3 (7.5)	
Median [IRQ]	18.0 [14.0, 24.0]	21.0 [16.0, 25.0]	18.0 [16.0, 22.0]	18.0 [13.3, 24.0]	15.0 [12.0, 24.0]	
240 min						
Mean (SD)	28.2 (12.5)	31.0 (13.0)	26.5 (9.3)	28.6 (14.8)	26.7 (12.6)	
Median [IRQ]	26.8 [20.0, 35.0]	28.0 [25.0, 35.0]	26.6 [23.0, 34.0]	24.0 [18.0, 36.0]	26.0 [18.0, 34.0]	
480 min						
Mean (SD)	35.5 [26.8, 46.3)	37.0 [31.0, 44.0)	34.0 [29.0, 49.0)	33.0 [26.0, 49.0)	36.0 [23.0, 45.0)	
Median [IRQ]	37.6 (16.7)	39.6 (16.9)	36.4 (13.1)	39.1 (18.3)	35.5 (18.5)	
24 h						
Mean (SD)	65.0 [46.8, 93.7)	65.0 [55.0, 104)	71.0 [48.0, 93.6)	71.0 [51.3, 93.0)	51.0 [42.0, 78.0)	
Median [IRQ]	72.9 (36.5)	81.9 (47.6)	74.1 (30.7)	74.7 (31.8)	61.3 (32.3)	
48 h						
Mean (SD)	117 (74.0)	137 (96)	118 (67.5)	121 (63.6)	90.8 (57.3)	
Median [IRQ]	99.0 (65.2, 136)	118.0 (73.2, 147)	94.3 (73.2, 135)	112.0 (72.0, 130)	73.5 (52.0, 120)	
72 h						

Mean (SD)	145 (95.6)	170 (123)	156 (97.7)	146 (67.0)	109 (73.3)
Median [IRQ]	127 [77.5, 170]	150 [88.2, 170]	128 [90.0, 189]	129 [97.0, 178]	89.0 [56.8, 147]

PACU, postoperative care unit, G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

## Acute pain measurements during postoperative care

Postoperative mean change in NRS measured at rest over the first 24 h differed significantly between groups G4 and G1 (standardized effect size: 0.17, 95% CI: 0.013–0.32, P = 0.033), but not between group G3 and G1 (standardized effect size: -0.097, 95% CI: -0.25–0.059, P = 0.223) or G2 and G1 (standardized effect size -0.052, 95% CI: -0.21–0.10, P = 0.51) (Fig 3A). Age, sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids had no effect on the results.



**Figure 3.** A) Patient-reported numerical rating scale (NRS) values at rest during the first 24 h in four patient-controlled analgesia (PCA) treatment groups G1-G4. Box plots show the median and 25–75th percentiles, and the whiskers indicate the minimum and maximum. (B) Risk ratios (95% CI) for reporting NRS value 4 or higher. PACU, postoperative care unit; CI, confidence interval.

To evaluate the effect of patient satisfaction, we analyzed the risk of having NRS >3 at rest at different timepoints during PACU treatment. For this purpose, NRS values were dichotomized depending on the pain level that patients experienced (NRS >3 or NRS  $\le$ 3). Although patient satisfaction, measured by patient-reported NRS was smaller in groups G2–G4 than group G1 at the end of PACU treatment, the finding was not statistically significant (Fig 3B).

## Postoperative sedation

At arrival to PACU, median (IQR) RASS was -1 (-2–0), and all patients were cooperative. RASS increased to 0 (-1 to 0) within the following 30 minutes. After 60 minutes, all patients were fully awake (median [IQR] RASS: 0 [0, 0]), and they remained fully awake until the end of the study. No significant differences in RASS scores were present between the groups during the 72-hour follow-up (Table 3).

---- Table 3 here ----

**Table 3.** Opioid related adverse events during the study.

Adverse effect		All	G1	G2	G3	G4
Sedation (F scale)	RASS-					
0 min		-1 [-2, 0] <sup>1</sup>	-1 [-2, 0]	-1 [-3, 0]	-1 [-1,0]	-1 [-2, 0]
5 min		-1 [-2, 0]	-1 [-2, 0]	0 [-1, 0]	0 [0,-1]	-1 [-1, 0]
30 min		0 [0, 1]	0 [0,-1]	0 [-1, 0]	0 [-1, 1]	0 [-1, 0]
60 min		0 [0, 0]	0 [0,-1]	0 [0, 0]	0 [0, 0]	0 [0, 0]
2 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
4 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
8 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
24 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
PONV		n=100	n=23	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	2 (8)	3 (12)	6 (24)	5 (22)
	No (%)	82 (82)	23 (92)	22 (88)	19 (76)	18 (78)

48 hr	Yes (%) No (%)	11 (11) 90 (90)	2 (8) 21 (84)	1 (4) 24 (96)	5 (20) 20 (80)	3 (13) 20 (87)
72 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
	No (%)	90 (90)	21 (84)	24 (96)	20 (80)	20 (87)
Pruritus		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	4 (16)	7 (28)	4 (16)	1 (4)
	No (%)	84 (84)	21 (84)	18 (72)	21 (84)	24 (96)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24
72 hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)
Unpleasa	nt dreams	n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	9 (9)	2 (8)	2 (8)	2 (8)	3 (12)
	No (%)	91 (91)	23 (92)	23 (92)	23 (92)	22 (88)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24 (96)
72hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)

<sup>&</sup>lt;sup>1</sup> RASS-scale given as median [interquartile range]

RASS, Richmond Agitation-Sedation Scale; PONV, postoperative nausea and vomiting; G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

### Opioid-related adverse effects

Opioid-related adverse events during the study are summarized in Table 3. Nausea and vomiting were the most frequent adverse events. At 24 h after PCA start, 16% of patients (n = 16) reported nausea. Increasing ketamine dose seemed to increase the incidence of PONV, but the changes

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

medications were required during the study.

were not statistically significant. Similarly, no differences were seen at the end of 48- and 72-h follow-up. We analyzed these adverse effects further with logistic regression. Our results indicate that preoperative weak opioid use increased the incidence of PONV significantly (odds ratio: 9.23, 95% CI: 1.4–75). Adjuvant ketamine in PCA had no effect (odds ratio: 3.9, 95% CI: 0.68–4.7) on PONV, and after changing to normal PCA with only oxycodone at 24 h, the incidence of PONV did not change (odds ratio: 0.53, 95% CI: 0.62–4.7). At 24 h after PCA start, 16% of patients (n = 16) reported pruritus (Table 3). The PCA treatment groups did not show statistically significant differences at any of the three time points (24, 48, or 72 h after the start of PCA). Similarly, the incidence of pruritus did not change after changing to normal PCA with oxycodone only. Nine patients (9%) reported nightmares or unpleasant dreams (Table 3). The groups showed no difference in this regard, and the incidence did not change after changing to normal PCA with oxycodone only. Age, sex, weight, chronic pain, and prior use of gabapentinoids had no effect on the results. Other adverse effects There were no severe adverse effects. None of the patients developed respiratory insufficiency requiring invasive or non-invasive ventilation during the 72-h study period. No rescue

#### Discussion

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

This randomized, double-blind, placebo-controlled study evaluated the effect of adding incremental doses of S-ketamine to oxycodone PCA in patients who underwent major lumbar spinal fusion surgery. Our results demonstrate that patients who received oxycodone:S-ketamine ratio 1:0.75 (a bolus containing oxycodone 1 mg + S-ketamine 0.75mg per ml) for postoperative analgesia consumed significantly less oxycodone at 24 h postoperatively compared with participants who received lower S-ketamine doses or oxycodone alone. A significant beneficial effect in mean change in pain intensity at rest was seen in the group receiving 0.75 mg ml<sup>-1</sup> S-ketamine in oxycodone PCA compared with patients receiving lower doses of ketamine or oxycodone alone. Cumulative oxycodone dose or adjunct S-ketamine did not significantly influence postoperative nausea and vomiting. Occurrence of pruritus, nightmares, or unpleasant dreams did not differ significantly among study groups. Major spinal surgery is increasing in frequency and complexity. It is associated with severe postoperative pain, which is not easily amenable to regional anesthesia and requires a multimodal approach. This is a crowded field of clinical research, with many previous studies evaluating various single doses of ketamine with different opioids in many types of surgery. Yet, there is little previous data that assesses the effect of adjunct ketamine to an IV opioid-PCA exclusively after lumbar spinal fusion surgery in an opioid-naïve patient population. A recent review and meta-analysis evaluated the effect of perioperative ketamine for analysis in spine surgery.<sup>24</sup> However, in most of the included trials, ketamine was administered intraoperatively followed by postoperative IV-PCA or ketamine was given both as a pre-incisional bolus and as a postoperative IV-PCA with a background infusion and a bolus on-demand. 25,26 This may confuse evaluation of the analgesic effect of IV-PCA administration of ketamine with an opioid.

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

Additionally, the meta-analysis included patients undergoing lumbar microdiscectomy with postoperative opioid IV-PCA.<sup>27</sup> It could be anticipated that pain after lumbar microdiscectomy is less severe than after major lumbar spinal fusion surgery, and thus postoperative conditions are not comparable. Furthermore, one previous study was an open-label trial<sup>28</sup> and another had only female patients.<sup>29</sup> making it difficult to generalize results. Previous studies have shown an opioid-sparing effect of intravenous low-dose ketamine after spine surgery in opioid-dependent patients. <sup>30, 31</sup> Additionally, Loftus (2010) and Nielsen (2017) showed that the benefit of ketamine increased with the amount of preoperatively administered opioids. <sup>30, 31</sup> Recently Nielsen et al. (2019) showed that perioperative intravenous S-ketamine reduced analgesic use and pain and improved labor market attachment of opioid-dependent patients one year after spine surgery.<sup>32</sup> Another recent study further confirmed that postoperative low-dose ketamine infusion reduced hydromorphone requirements for the first 24 h after spinal fusion surgery in opioid-tolerant patients, but not in opioid-naïve patients.<sup>33</sup> However, it is recognized that previous opioid use alters pain processing, and these patients typically require higher opioid doses postoperatively. Thus, results of these studies cannot be directly applied to all patients. Although the effect of adjunct ketamine in the opioid-tolerant patient population after lumbar fusion surgery is quite well established, the effect in the opioid-naïve population is less clear. Additionally, the optimal dose of adjunct ketamine in an opioid IV-PCA is unknown. Data indicating low incidence of ketamine-related adverse events (PONV and CNS adverse events) has been consistent in previous studies. 11,12,33 Likewise, our study showed that adjunct Sketamine in oxycodone IV-PCA was well tolerated. There are several reports of ketamine's beneficial effect on analgesia, opioid-sparing, and PONV in the postoperative period, without

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

increasing the risk for hallucinations. However, the opioid:ketamine ratio in IV-PCA in previous studies was heterogeneous, ranging from 1:0.5 to 1:2.5, and these studies were also heterogeneous in regard to the opioid used, anesthesia methodology, type of surgery, patient population, and use of racemic- or S-ketamine. 34,35 Our study has limitations. Our study was designed to detect a difference in 24 h cumulative oxycodone consumption, which was the primary outcome. The beneficial effect of adjunct Sketamine in an oxycodone IV-PCA in reducing the 24 h oxycodone consumption did not correlate with a reduction in opioid-related side effects, but this could be secondary to a lack of power. On the other hand, the strengths of our study include that the patient population was homogenous across study groups, consisting of adult men and women who underwent posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation. Postoperative analgesic consumption as a surrogate measure for pain has been criticized on the basis of reports that it is skewed, where a minority of patients consume more than half of the postoperative analysesic. A recent study encouraged reporting categorized parameters as more clinically intuitive. 36 As discussed before, dichotomizing continuous measures leads to several problems.<sup>37</sup> Previously, analgesic consumption has been analyzed with point estimates or determining area under the curve, but both of these methods introduce considerable bias. Statisticians recommend using a model-based approaches, which has been used here. Therefore, both mean (SD) and median (IQR) have been reported. From a clinical perspective, it may be unrealistic to achieve a totally pain-free state after major surgical trauma following surgery such as instrumented lumbar spinal fusion. We think that IV-PCA enables the patient to titrate the opioid to reach a certain individual, tolerable pain intensity level. Therefore, we consider that changes in cumulative opioid consumption could serve as an acceptable surrogate for changes in

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

postoperative pain. However, we also evaluated the outcome by using risk ratios for pain intensity NRS >3 as a surrogate for perioperative pain experience, and adjunct S-ketamine seemed to decrease the likelihood of pain exceeding NRS >3. Our study adds new data considering the optimal dose of adjunct S-ketamine to an oxycodone IV-PCA after lumbar spinal fusion surgery. Because the oxycodone:S-ketamine ratio of 1:0.75 was not associated with increased adverse events, we suggest that future studies aimed at solving the optimal opioid:S-ketamine ratio evaluate that dose and higher, possibly with pharmacokinetic testing to characterize the dose-concentration-effect relationship. In conclusion, IV-PCA containing adjunct S-ketamine with oxycodone at a ratio of 1:0.75 after major lumbar spinal fusion surgery is effective in decreasing the total oxycodone consumption at 24 h after surgery. This oxycodone:S-ketamine ratio is also well tolerated. As previous studies have mainly focused on intraoperative administration, even showing no analgesic effect of intraoperative S-ketamine in opioid-naïve patients<sup>38</sup>, this finding adds new data to the feasibility of adjunct S-ketamine with oxycodone for postoperative pain management after major lumbar spinal fusion surgery.

405

406

407

408

409

410

411

412

413 414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

Eliisa Löyttyniemi, MSc, Institute of Biomedicine, University of Turku gave invaluable

statistical help. The nursing staff of K- and T-operating units, TYKS ORTO, and neurosurgical

430

431

432

433

434

435

436

437

438

#### References

- 1. Gerbershagen HJ, Aduckathil S, van Wijck AJM, Peelen LM, Kalkman CJ, Meissner W.
- Pain intensity on the first day after surgery: a prospective cohort study comparing 179
- surgical procedures. *Anesthesiology*. 2013;118:934–944.
- 443 2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention.
- 444 *Lancet.* 2006;367:1618–1625.
- 445 3. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a
- national survey suggest postoperative pain continues to be undermanaged. *Anesth Analg.*
- 2003;97:534–540.
- 448 4. Kurd MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine
- surgery. *J Am Acad Orthop Surg.* 2017;25:260–268.
- 450 5. Cozowicz C, Bekeris J, Poeran J, Zubizarreta N, Schwenk E, Girardi F, et al. Multimodal
- 451 pain management and postoperative outcomes in lumbar spine fusion surgery: a
- population-based cohort study. Spine (Phila Pa 1976). 2020;45:580–589.
- 453 6. McNicol E, Ferguson MC, Hudcova J. Patient-controlled analgesia versus non-patient
- 454 controlled analgesia for postoperative pain. *Cochrane Database Syst Rev.*
- 455 2015;6:CD003348.
- Dinges HC, Otto S, Stay DK, Bäumlein S, Waldmann S, Kranke P, et al. Side effect rates
- of opioids in equianalgesic doses via intravenous patient-controlled analgesia: a systematic
- review and network meta-analysis. *Anesth Analg.* 2019;129:1153–1162.
- 8. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical
- pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin*
- *Pharmacokinet.* 2016;55:1059–1077.

- 9. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of
- 463 pain. Cell. 2009; 139:267–284.
- Hirota K, Lambert DG. Ketamine: new uses for an old drug? Br J Anaesth. 2011;107:123–
- 465 126.
- 466 11. Woolf CJ. Pain amplification—a perspective on the how, why, when, and where of central
- sensitization. J Appl Biobehav Res. 2018;23:e12124.
- Heesen M, Bell RF, Straube S, Moore RA, et al. Perioperative
- intravenous ketamine for acute postoperative pain in adults. *Cochrane Database Syst Rev.*
- 470 2018;12:CD012033.
- 471 13. Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding ketamine to
- an opioid in a patient-controlled analgesia device for the control of postoperative pain:
- systematic review and meta-analyses of randomized controlled trials with trial sequential
- analyses. Pain. 2016;157:2854–2864.
- 475 14. Sveticic G, Gentilini A, Eichenberger U, Luginbühl M, Curatolo M. Combinations of
- 476 morphine with ketamine for patient-controlled analgesia: a new optimization method.
- *Anesthesiology.* 2003;98:1195–11205.
- 478 15. Sveticic G, Eichenberger U, Curatolo M. Safety of mixture of morphine with ketamine for
- postoperative patient-controlled analgesia: an audit with 1026 patients. Acta Anaesthiol
- 480 *Scand.* 2005;49:870–875.
- 481 16. Sveticic G, Farzanegan F, Zmoos P, Zmoos S, Eichenberger U, Curatolo M. Is the
- combination of morphine with ketamine better than morphine alone for postoperative
- 483 intravenous patient-controlled analgesia? *Anesth Analg.* 2008;106:287–293, table of
- 484 contents.

- 485 17. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The
- influence of age on propofol pharmacodynamics. *Anesthesiology*. 1999; 90:1502–1516.
- 487 18. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Billard V, et al. Influence of
- age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model
- development. *Anesthesiology*. 1997; 86:10–23.
- 490 19. Lin T-F, Yeh Y-C, Lin F-S, Wang Y-P, Sun W-Z, Fan S-F. Effect of combining
- dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth*.
- 492 2009;102:117–122.
- 493 20. Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of
- some recommended measures of effect size. *Trends Sport Sci.* 2014;1:19–25.
- 495 21. RStudio Team. RStudio: Integrated Development Environment for R. 2020. Available at:
- 496 <a href="http://www.rstudio.com/">http://www.rstudio.com/</a>. Accessed: 13 March, 2020.
- 497 22. R Core Team. R: A Language and Environment for Statistical Computing. 2019. Available
- 498 at: http://www.r-project.org/. Accessed: 13 March 2020.
- 499 23. Austin PC. Using the standardized difference to compare the prevalence of a binary
- variable between two groups in observational research. *Commun Stat Simul Comput*.
- 501 2009;38:1228–1234.
- 502 24. Pendi A, Field R, Farhan S-D, Eichler M, Bederman SS. Perioperative ketamine for
- analgesia in spine surgery: a meta-analysis of randomized controlled trials. Spine (Phila Pa
- 504 *1976*). 2018; 43:E299–E307.
- 505 25. Pacreu S, Fernández Candil J, Moltó L, Carazo J, Fernández Galinski S. The perioperative
- combination of methadone and ketamine reduces post-operative opioid usage compared
- with methadone alone. *Acta Anaesthiol Scand.* 2012;56:1250–1256.

- 508 Yeom JH, Chon M-S, Jeon WJ, Shim J-H. Perioperative ketamine with the ambulatory elastometric infusion pump as an adjuvant to manage acute postoperative pain after spinal 509 fusion in adults: a prospective randomized trial. Korean J Anesthesiol. 2012;63:54–58. 510 27. Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and 511 morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996;43:212–215. 512 513 28. Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous low-dose ketamine reduces the consumption of postoperative patient-controlled analgesia morphine 514 after spine surgery. Acta Anaesthesiol Taiwan. 2013;51:14–17. 515 516 29. Song JW, Shim JK, Song Y, Yang SY, Park SJ, Kwak YL. Effect of ketamine as an adjunct to intravenous patient-controlled analgesia, in patients at high risk of postoperative 517 nausea and vomiting undergoing lumbar spinal surgery. Br J Anaesth. 2013;111:630–635. 518 30. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK. et al. 519 Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent 520 patients with chronic back pain undergoing back surgery. Anesthesiology. 2010;113:639-521 646. 522 Nielsen RV, Fomsgaard JS, Siegel H, Martuseviicius R, Nikolajsen L, Dahl JB, al. 523 524 Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded 525 526 trial. Pain. 2017;158:463-470. 527 32. Nielsen RV, Fomsgaard JS, Nikolajsen L, Dahl JB, Mathiesen O. Intraoperative S-
- ketamine for the reduction of opioid consumption and pain one year after spine surgery: a randomized clinical trial of opioid-dependent patients. *Eur J Pain*. 2019;23:455–460.

- 530 Boenigk K, Echevarria GC, Nisimov E, Bergen Granell AE von, Cuff GE, Wang J, Atchabahian A. Low-dose ketamine infusion reduces postoperative hydromorphone 531 requirements in opioid-tolerant patients following spinal fusion: a randomised controlled 532 trial. Eur J Anaesthesiol. 2019;36:8–15. 533 Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J. Ketamine added to morphine 534 34. 535 or hydromorphone patient-controlled analgesia for acute postoperative pain in adults: a systematic review and meta-analysis of randomized trials. Can J Anaesth. 2016;63:311-536 325. 537 538 35. Carstensen M, Møller AM. Adding ketamine to morphine for intravenous patientcontrolled analgesia for acute postoperative pain: a qualitative review of randomized trials. 539 *Br J Anaesth.* 2010;104:401–406. 540
- Moore RA, Mhuircheartaigh RJN, Derry S, McQuay HJ. Mean analgesic consumption is
   inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative
   suggestion. *Eur J Anaesthesiol*. 2011;28:427–432.
- Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ*.
   2006;332:1080.
- 546 38. Brinck ECV, Maisniemi K, Kankare J, Tielinen L, Tarkkila P, Kontinen VK. Analgesic
  547 effect of intraoperative intravenous S-ketamine in opioid-naïve patients after major lumbar
  548 fusion surgery is temporary and not dose-dependent: a randomized, double-blind, placebo549 controlled clinical trial. *Anesth Analg.* 2021;132:69–79.



# CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction	20	Scientific background and explanation of rationals	4
Background and objectives	2a	Scientific background and explanation of rationale	
	2b	Specific objectives or hypotheses	4-5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	-
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7,9
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	-

Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	7
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	7
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10-11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	-
Results Participant flow (a diagram is strongly	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	12
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	12
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	12, table 1

Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	12
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	15, table 2
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	20-21
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	-
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	21
<b>Discussion</b> Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	24
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	25
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	25
Other information			
Registration	23	Registration number and name of trial registry	6
Protocol	24	Where the full trial protocol can be accessed, if available	1,6
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	8